Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years, both drugs have become the company’s key top-line drivers. In the ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...

When Zepbound, Eli Lilly's highly anticipated weight loss drug, hit the market a year and a half ago, it marked a turning point for the accessibility of weight loss drugs. Since then, Zepbound, the ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

But Eli Lilly did it, climbing nearly 117% over the past year. This wasn't just a random happening, but instead evidence investors are very excited about what's to come for this pharma giant.

Eli Lilly said it has started selling single-dose vials of its uber-popular weight loss drug Zepbound as demand soars – and the smaller doses cost 50% less than all other obesity medicines.

Eli Lilly weight loss drug Zepbound now available for half its usual price You can now get 2.5-milligram, single-dose vials of Zepbound for $399 per month through Lilly's direct-to-consumer website.

Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound. This comes at a time when compounded GLP-1 medications have risen in popularity. Investor Alert: Our 10 best stocks ...

Eli Lilly’s weight loss drug Zepbound generated more than $175 million in just its first few weeks on the market. The company is addressing a market that could reach $100 billion by 2030 ...